Potential New Treatment for Alpha-1 Antitrypsin Deficiency

Trial Objective

Potential New Drug Alvelestat for AATDResearchers want to see if a new drug, alvelestat, improves the symptoms of lung disease caused by COPD due to alpha-1 antitrypsin deficiency (AATD), as well as symptoms of the AATD.

Enrollment

Active Clinical Trials Currently Recruiting

Who Can Participate

People between the ages of 18-80 with chronic obstructive pulmonary disease (COPD) due to alpha-1 antitrypsin deficiency (AATD) may be eligible to participate.

Age: 18-80    Gender: Any Gender


Estimated Time Commitment

Up to 5 months



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Kristina Eliopoulos

Kristina Eliopoulos
303.270.2622

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

National Institutes of Health, University of Alabama at Birmingham

Co-Investigators


Request More Information

Complete this form to learn more about this study and see if you qualify.


*
*
*
*